Nautilus Biotechnology (NASDAQ:NAUT) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Nautilus Biotechnology (NASDAQ:NAUT) released its quarterly earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.04, Zacks reports. During the same quarter in the prior year, the firm posted ($0.13) earnings per share.

Nautilus Biotechnology Trading Down 4.3 %

Shares of Nautilus Biotechnology stock traded down $0.12 during trading on Wednesday, hitting $2.65. The stock had a trading volume of 43,413 shares, compared to its average volume of 74,739. Nautilus Biotechnology has a 12 month low of $2.19 and a 12 month high of $3.45. The business’s 50-day moving average is $2.75 and its 200 day moving average is $2.62. The firm has a market cap of $332.34 million, a price-to-earnings ratio of -4.73 and a beta of 1.22.

Insider Buying and Selling

In related news, VP Mary E. Godwin sold 35,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $2.85, for a total value of $99,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 40.50% of the stock is owned by company insiders.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.